Poster Presentation ESA-SRB-APEG-NZSE 2022

Cushioning the blow of ectopic ACTH syndrome (#321)

Lauren Burrage 1 , Ashim Sinha 1 , Amanda Love 2
  1. Queensland Health, Cairns North, QLD, Australia
  2. Department of Endocrinology and DIabetes, Royal Brisbane and Women's Hospital, Brisbane, QUEENSLAND, Australia

A 77-year-old male presented with rapid onset peripheral oedema and proximal myopathy. Computed tomography revealed diffusely enlarged adrenal glands, liver metastases, and a small spiculated lung lesion. Cushing’s syndrome was confirmed with markedly elevated 24-hour urine free cortisol levels. The 8mg dexamethasone suppression test indicated an ectopic source of cortisol. FDG-PET revealed low grade uptake in the lung and hepatic lesions. Ga68-DOTATATE PET was negative. Core biopsy of a liver lesion confirmed metastatic neuroendocrine tumour (NET) with immunohistochemistry suggesting a primary lung origin. Metyrapone and ketoconazole successfully reduced 24-hour urine free cortisol but multiple complications of hypercortisolism still developed. The absence of DOTATATE uptake eliminated the possibility of peptide receptor radionuclide therapy (PRRT). Other management strategies of ectopic ACTH syndrome (EAS) were considered and bilateral adrenalectomy was ultimately performed. The metastatic NET was managed with active surveillance and remains stable after eight months.

 

EAS is a rare condition that reflects excessive ACTH secretion by NETs, most commonly by well-differentiated pulmonary NETs (1,2,3). Management of metastatic EAS requires consideration of the tumour risk against the hormonal risk. Options for tumour control are limited in metastatic EAS as there is minimal evidence for targeted therapies although PRRT may be effective (1,2,3). Management of hypercortisolism includes pharmacologic treatment, which is limited by tolerability and efficacy, or bilateral adrenalectomy, which is effective but associated with post-operative morbidity and permanent glucocorticoid requirement (1,2,4). In several large case series, bilateral adrenalectomy was required for most patients with metastatic disease and was associated with better survival (3,4,5,6). In conclusion, EAS is most commonly due to pulmonary NETs which often have an excellent tumour prognosis due to their indolent nature. In such cases, management of hypercortisolism is a priority and bilateral adrenalectomy may be required, particularly in patients with metastatic disease to provide effective long-term control.

 

  1. Young J, Haissaguerre M, Viera-Pinto O, Chabre O, Baudin E, Tabarin A. Cushing's syndrome due to ectopic ACTH secretion: an expert operational opinion. Eur J Endocrinol. 2020;182(4):R29-R58. doi:10.1530/EJE-19-0877
  2. Hayes AR, Grossman AB. The Ectopic Adrenocorticotropic Hormone Syndrome: Rarely Easy, Always Challenging. Endocrinol Metab Clin North Am. 2018;47(2):409-425. doi:10.1016/j.ecl.2018.01.005
  3. Davi' MV, Cosaro E, Piacentini S, et al. Prognostic factors in ectopic Cushing's syndrome due to neuroendocrine tumors: a multicenter study. Eur J Endocrinol. 2017;176(4):453-461. doi:10.1530/EJE-16-0809
  4. Landry JP, Clemente-Gutierrez U, Pieterman CRC, et al. Management of adrenocorticotropic hormone-secreting neuroendocrine tumors and the role of bilateral adrenalectomy in ectopic Cushing syndrome. Surgery. 2022;172(2):559-566. doi:10.1016/j.surg.2022.03.014
  5. Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab. 2006;91(2):371-377. doi:10.1210/jc.2005-1542
  6. Ilias I, Torpy DJ, Pacak K, Mullen N, Wesley RA, Nieman LK. Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin Endocrinol Metab. 2005;90(8):4955-4962. doi:10.1210/jc.2004-2527